Enterovirus Infections - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 44 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Enterovirus Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Enterovirus Infections - Pipeline Review, H2 2014', provides an overview of the Enterovirus Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Enterovirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterovirus Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Enterovirus Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Enterovirus Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Enterovirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Enterovirus Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Enterovirus Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Enterovirus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Enterovirus Infections Overview 6
Therapeutics Development 7
Pipeline Products for Enterovirus Infections - Overview 7
Pipeline Products for Enterovirus Infections - Comparative Analysis 8
Enterovirus Infections - Therapeutics under Development by Companies 9
Enterovirus Infections - Therapeutics under Investigation by Universities/Institutes 10
Enterovirus Infections - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Enterovirus Infections - Products under Development by Companies 14
Enterovirus Infections - Products under Investigation by Universities/Institutes 15
Enterovirus Infections - Companies Involved in Therapeutics Development 16
Beijing Minhai Biotechnology Co., Ltd 16
Medigen Biotechnology Corporation 17
Myelo Therapeutics GmbH 18
Shanghai Zerun Biotechnology Co., Ltd. 19
Sinovac Biotech Ltd. 20
Enterovirus Infections - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 27
Drug Profiles 29
coxsackievirus [serotype A16] vaccine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Drug to Inhibit MMP12 for Coxsackievirus Type B3 Infection - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Enterovirus [EV71] Vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
enterovirus 71 vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
EV-71 Vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
EV71 vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
KR-22809 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
KR-22865 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Myelo-001 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
OBR-5340 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
TP-219 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Enterovirus Infections - Recent Pipeline Updates 41
Enterovirus Infections - Product Development Milestones 42
Featured News & Press Releases 42
May 28, 2013: Experimental Vaccine Protects Kids Against Hand, Foot And Mouth Disease, Clinical Trial Shows 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables
Number of Products under Development for Enterovirus Infections, H2 2014 7
Number of Products under Development for Enterovirus Infections - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Enterovirus Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2014 16
Enterovirus Infections - Pipeline by Medigen Biotechnology Corporation, H2 2014 17
Enterovirus Infections - Pipeline by Myelo Therapeutics GmbH, H2 2014 18
Enterovirus Infections - Pipeline by Shanghai Zerun Biotechnology Co., Ltd., H2 2014 19
Enterovirus Infections - Pipeline by Sinovac Biotech Ltd., H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
Enterovirus Infections Therapeutics - Recent Pipeline Updates, H2 2014 41